

1 **A next generation CRISPR diagnostic tool to survey drug resistance in Human African**  
2 **Trypanosomiasis.**

3

4 Authors and affiliations

5 Elena Pérez Antón<sup>1</sup>, Annick Dujancourt-Henry<sup>1</sup>, Brice Rotureau<sup>2,3\*</sup>, Lucy Glover<sup>1\*</sup>

6

7 <sup>1</sup>Trypanosome Molecular Biology Unit, Institut Pasteur, Université de Paris, Paris, France

8 <sup>2</sup>Trypanosome Transmission Group, Trypanosome Cell Biology Unit, INSERM U1201, Institut

9 Pasteur, Université de Paris, Paris, France

10 <sup>3</sup>Parasitology Unit, Institut Pasteur of Guinea, Conakry, Guinea

11 \*Corresponding authors: [lucy.glover@pasteur.fr](mailto:lucy.glover@pasteur.fr); [brice.rotureau@pasteur.fr](mailto:brice.rotureau@pasteur.fr)

12

13

14

15

16

17

18

19

20 **Keywords**

21 Human African trypanosomiasis, *Trypanosoma brucei gambiense*, SHERLOCK, crRNA,

22 Cas13a, drug-resistance, acoziborole, melarsoprol, pentamidine.

23

24

25

26

27

28

29

30

31

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 32 **Abstract**

33 The WHO aims to eliminate the *gambiense* form of human African trypanosomiasis (HAT) by  
34 2030. With the decline of reported cases, maintaining efficient epidemiological surveillance is  
35 essential, including the emergence of drug-resistant strains. We have developed new highly  
36 specific diagnostic tools using Specific High-Sensitivity Reporter Enzymatic UnLOCKing  
37 (SHERLOCK) technology for monitoring the presence of drug-resistant genotypes that (1) are  
38 already circulating, such as the AQP2/3<sub>(814)</sub> chimera providing resistance to pentamidine and  
39 melarsoprol, or (2) could emerge, such as *TbCPSF3* (N<sup>232</sup>H), associated to acoziborole  
40 resistance in lab conditions. The melarsoprol - pentamidine AQP2/3<sub>(814)</sub> SHERLOCK assay  
41 detected RNA from both cultured parasites and field isolated strains from gHAT patients in  
42 relapse following treatment. The acoziborole *CPSF3*<sub>(SNV)</sub> SHERLOCK assay discriminated  
43 between wild-type *CPSF3* RNA and *CPSF3* with a single A-C mutation that confers resistance  
44 to acoziborole *in vitro*.

45

## 46 **Introduction**

47 Human African trypanosomiasis (HAT), or sleeping sickness, is one of the 21 conditions  
48 identified as a neglected tropical diseases by the World Health Organization (WHO) <sup>1</sup>. Caused  
49 by an infection with the extracellular protozoan parasite *Trypanosoma (T) brucei (b) gambiense*  
50 (gHAT) in West and Central Africa or *T. b. rhodesiense* (rHAT) in East and Southern Africa.  
51 HAT infections follow a typical clinical pattern, initiating with intermittent fever and  
52 lymphadenopathy during a first step of blood and lymph infection (stage 1) and advancing to  
53 severe neurological symptoms when the parasites invade the cerebrospinal fluid (stage 2), and  
54 ultimately death if untreated. The major difference in disease progression between *T. b.*  
55 *gambiense* and *T. b. rhodesiense* is that the former is chronic lasting over several months to  
56 years and the latter acute, lasting for several weeks. There is currently no prophylactic drug  
57 available for HAT, the approved chemotherapies depend on the parasite species and the stage  
58 of the disease<sup>1</sup>. For gHAT, children under the age of 6 or less than 20 kg are, as a first choice,  
59 treated with pentamidine for stage 1 or NECT for stage 2. Patients older than 6 years old and  
60 more than 20 kgs are treated with fexinidazole at stage 1, or with fexinidazole (if white blood  
61 cell count in the cerebrospinal fluid is lower than 100/ $\mu$ L) or NECT at stage 2 <sup>2</sup>. If relapse is  
62 detected, patients are treated with NECT. For rHAT, children under the age of 6 or less than 20  
63 kg are treated with suramin as a first choice for stage 1 or melarsoprol for stage 2, and if relapse

64 is seen, fexinidazole may be given for compassionate use <sup>2</sup>. Patients older than 6 years old and  
65 more than 20 kgs are treated with fexinidazole for both stage 1 and 2, yet if relapse is detected,  
66 patients are treated with suramin or melarsoprol <sup>2</sup>. Both suramin and pentamidine require  
67 prolonged intravenous administration, melarsoprol causes encephalopathic syndrome that is  
68 fatal in up to one in ten patients and NECT involves a long and complex dose regime with  
69 intravenous eflornithine alongside oral nifurtimox over the course of two weeks at hospital <sup>3</sup>.  
70 These drugs present either with side effects or, are logistically challenging to administer.  
71 Accurate diagnosis and staging of the disease are key for the selection of the appropriate drug  
72 treatment, but diagnosis is based on a tedious algorithm, including lumbar puncture as a  
73 confirmatory test for the most advanced stage of gHAT<sup>4</sup>. The high toxicity of some of these  
74 drugs, especially melarsoprol, as well as the complex administration of NECT make access to  
75 treatment challenging and have prevented implementation of mass treatment as a method of  
76 combating the disease <sup>5</sup>.

77 Fexinidazole was approved in 2019 by the European Medicines Agency <sup>6</sup>, as a 10-day oral  
78 treatment regime that must be taken with food for optimal absorption, yet with treatment  
79 emergent adverse events such as vomiting and nausea increases the risk of non-compliance <sup>5,7</sup>.  
80 Due to the high-risk of non-compliance leading to the ingestion of suboptimal curative doses,  
81 the possibility of relapse is of concern – especially as it may occur late, up to 24 months post-  
82 treatment <sup>5</sup>, which could increase the risk of the emergence of drug-resistance. Resistance to  
83 fexinidazole is readily generated under laboratory conditions <sup>8</sup> and occurs through a similar  
84 mechanism as that to nifurtimox, via mutation of the nitroreductase (NTR) gene <sup>8</sup>. Therefore,  
85 there already exists the potential that previous use of nifurtimox in the field may have already  
86 led to the emergence of fexinidazole resistant parasites <sup>9</sup>. Fexinadazole is currently the only oral  
87 drug approved for treatment of both stage 1 and 2 gHAT and rHAT <sup>2,5</sup>. Drug resistance is not  
88 uncommon in the treatment of HAT, melarsoprol resistance emerged as early as 1970 and was  
89 widespread by 1990 <sup>10,11</sup>, while resistance to both eflornithine and nifurtimox can be generated  
90 *in vitro* <sup>3</sup>.

91 In a context where the therapeutic arsenal for treating HAT is limited, the emergence of drug  
92 resistance is possible where a selective pressure to survive is applied to parasites, placing both  
93 existing and potential future drug treatments at risk. Pentamidine and melarsoprol share the  
94 same mechanism of entry into the parasite cell through the adenosine transporters and the  
95 aquaglyceroporin channels (AQPs) <sup>10,12</sup>. Among the three aquaglyceroporin genes of *T. brucei*  
96 (*TbAQP1-3*) <sup>13</sup>, the deletion of the *AQP2* locus is related to the melarsoprol-pentamidine cross-  
97 resistance in bloodstream-forms, increasing their effective concentrations (EC<sub>50</sub>) by 2- to 15-

98 fold, respectively <sup>12</sup>. Several distinct mutations in the *AQP2-AQP3* genes have been associated  
99 with relapse of HAT after treatment with melarsoprol in patients from the Mbuji-Mayi region  
100 of the Democratic Republic of the Congo <sup>14,15</sup> and the Mundri county of South Sudan<sup>14,16</sup> . One  
101 specific chimera identified, a chimera containing the first 813 bp from *AQP2* and the last 126  
102 bp from *AQP3*, here termed AQP2/AQP3<sub>(814)</sub>, <sup>15</sup>, was associated with cross-reactivity to  
103 melarsoprol and pentamidine <sup>14</sup>.

104 Although not a frontline drug yet, acoziborole promises to be key in the efforts to eliminate  
105 HAT. Currently in phase III clinical trials, acoziborole could be approved for the treatment of  
106 both stages of gHAT by 2026 <sup>17</sup>, it is a single oral dose benzoxaborole derivative that shows  
107 high efficacy and safety. Its approval could eliminate the need for routine lumbar puncture and  
108 would allow the treatment of parasitology-negative suspects, as well as making treatment more  
109 accessible to patients living in remote areas <sup>17,18</sup>. The drug molecule binds to the active site of  
110 the Cleavage and Polyadenylation Specificity Factor 3 (CPSF3), which is involved in  
111 trypanosome mRNA processing <sup>19</sup>, inhibits polypeptide translation and reduces endocytosis of  
112 haptoglobin-hemoglobin <sup>20</sup>. However, resistance to acoziborole can be generated *in vitro*,  
113 through editing a single nucleotide in the *CPSF3* sequence <sup>21</sup>.

114 The CRISPR based diagnostic - Specific High-sensitivity Enzymatic Reporter unLOCKing  
115 (SHERLOCK) - first amplifies nucleic acid using recombinase polymerase amplification  
116 (RPA), which is then combined with the Cas13a nuclease, for target recognition via specific  
117 guides, and a fluorescent reporter linked to a quencher by nucleotides. Target sequence  
118 recognition activates Cas13a's 'collateral effect' of promiscuous ribonuclease activity. So far,  
119 SHERLOCK diagnostic assays have been developed for two protozoan parasites, African  
120 trypanosomes<sup>22</sup> and *Plasmodium*<sup>23</sup>. SHERLOCK is capable of detecting a few attomoles (10<sup>-18</sup>  
121 moles) of nucleic acids in a sample and its specificity was demonstrated by distinguishing  
122 between closely related Zika and dengue viruses in clinical isolates, or mutant strains with  
123 unique SNPs <sup>24-26</sup>. Here, we developed highly specific SHERLOCK assays that allow detection  
124 of specific drug-resistance associated mutations and that could be essential for epidemiological  
125 surveillance in the context of gHAT elimination and rHAT control.

126

## 127 **Methods**

### 128 **Trypanosome and RNA material**

129 *T. b. brucei* Lister 427 bloodstream form cells were cultured in HMI-11 medium with 10 %  
130 foetal bovine serum (Sigma-Aldrich) at 37 °C with 5% CO<sub>2</sub>. RNA extraction was carried out  
131 from culture harvest at 1x10<sup>6</sup> cell/mL. RNA extraction of *T. b. brucei* cells, *T. b. gambiense*  
132 cell pellets, and human embryonic kidney (HEK) 293T cells were carried using the RNeasy  
133 Mini kit (Qiagen). Lyophilized RNA extracted from *T. b. brucei* edited CPFS3<sup>19</sup> was  
134 resuspended in nuclease-free water.

135

### 136 **Table 1: Trypanosome strains and isolates used in this study.**

Species	Strain	Phenotype	Source	Ref
<i>T. b. brucei</i>	Wild type	-	<i>in vitro</i>	
<i>T. b. brucei</i>	AQP2/3 chimera	Resistance to melarsoprol	<i>in vitro</i>	15
<i>T. b. brucei</i>	CPFS3 A-C mutant	Resistanec to acoziborole	<i>in vitro</i>	19
<i>T. b. gambiense</i>	Wild type	-	<i>in vitro</i>	
<i>T. b. gambiense</i>	163AT	Resistance to melarsoprol	Human	15
<i>T. b. gambiense</i>	348BT	Resistance to melarsoprol	Human	15
<i>T. b. gambiense</i>	MBA	AQP2/3 chimera – no resistance	Human	15
<i>T. b. gambiense</i>	40AT	Resistance to melarsoprol	Human	14,15
<i>T. b. gambiense</i>	349 AT	Resistance to melarsoprol	Human	14,15
<i>T. b. gambiense</i>	K03048	Resistance to melarsoprol	Human	14,16
<i>T. b. gambiense</i>	Wild type	-	Human	15

137

### 138 **LwCas13a enzyme expression and purification**

139 The plasmid pC013-Twinstrep-SUMO-huLwCas13a (Addgene plasmid #90097) was used for  
140 the protein expression in *Escherichia coli* Rosetta™ 2(DE3) pLysS competent cells<sup>25</sup>. The  
141 protein expression and purification of *Leptotrichia wadei* Cas13a (*LwCas13a*) enzyme was  
142 performed as described in<sup>27</sup> with slight modifications<sup>22</sup>. TB medium was reconstituted by  
143 adding 47.8 g of TB powder to a 1-L flask, adding 8 mL of 100% (wt/vol) glycerol. Cell pellet  
144 was lysed with supplemented lysis buffer composed by 2 complete Ultra EDTA-free tablets  
145 (Roche), 500 mM NaCl, 100 mg lysozyme and 125-625 ng Deoxyribonuclease I from bovine  
146 pancreas (Sigma) to each 100 mL of lysis buffer. The *LwCas13a* was storage in single-use  
147 aliquots at -80°C to avoid freeze-thaw cycles.

### 148 **Design of RPA primers and crRNA**

149 RPA primer pairs were designed using NCBI Primer-BLAST<sup>28</sup> using the custom parameters  
150 specified in<sup>27</sup>. For the wild-type CPSF3 SHERLOCK we use the reference sequence  
151 XM\_839191.1 (Tb927.4.1340). For targeting the chimeric AQP2/AQP3<sub>(814)</sub> the reference  
152 sequence KF564935.1 (*T. b. gambiense* strain 40AT) was used. The RPA primers used in the  
153 study are included in Supplementary Table 1. RPA forward primers include at the 5' end, the  
154 T7 promoter sequence (5'-GAAATTAATACGACTCACTATAGGG-3') that allow *in vitro*  
155 transcription of the amplified target by T7 polymerase.

156 The DNA templates used to generate the crRNAs consist of: 1) the target sequence (5'-3') which  
157 will be the variable region between crRNA, also known as the spacer (with variable lengths  
158 from 20 to 28 nt), followed by 2) the direct repeat template common to all *Lw*Cas13a crRNAs  
159 (5'-GTTTTAGTCCCCTTCGTTTTTGGGGTAGTCTAGTCTAAATC-3'), followed by 3) the  
160 T7 promoter sequence at the 3' end (5'-CCCTATATAGTGAGTCGTATTAATTTC-3'), which  
161 will allow *in vitro* transcription of the guides. DNA templates used are listed in Supplementary  
162 Table 1. All of the oligonucleotides mentioned were synthesized by ThermoFisher.

### 163 ***In vitro* transcription and purification of crRNAs**

164 The crRNA synthesis was carried out using a DNA template and *in vitro* transcription mediated  
165 by T7 polymerase according to manufacturer's instructions using the HiScribe™ T7 Quick  
166 High Yield RNA Synthesis Kit (NEB), as previously described<sup>27</sup>. Briefly, we first annealed  
167 the crRNA DNA template and T7-3G oligonucleotide (5'-  
168 GAAATTAATACGACTCACTATAGGG-3') by denaturation for 5 min followed by slow  
169 cooling<sup>22</sup>. After *in vitro* transcription, the crRNAs were purified using magnetic beads  
170 (Agencourt RNAClean XP) and stored at 300 ng/μL in single-use aliquots at -80°C to avoid  
171 freeze-thaw cycles.

### 172 **SHERLOCK assay**

173 The Specific High Sensitivity Enzymatic Reporter unLOCKing (SHERLOCK) assay was  
174 performed as described in<sup>27</sup>. The SHERLOCK reaction is a combination of a pre-amplification  
175 method by a reverse transcription (RT) recombinase polymerase amplification (RPA)<sup>29</sup> and a  
176 specific RNA-target recognition by Cas13-CRISPR RNA-guide (crRNA) machinery  
177 (Abudayyeh et al., 2016). The RT-RPA was carried out using the TwistAmp Basic kit  
178 (TwistDx) following manufacturer's instructions for 45 min at 42 °C as described by<sup>22</sup>. The  
179 amplification step is followed by simultaneous *in vitro* transcription of the amplified target by

180 T7 polymerase (Biosearch technology) and detection of the *LwCas13a*-crRNA using the same  
181 condition as described by <sup>22</sup>. For this purpose, 4  $\mu$ L of the RT-RPA product of each replicate  
182 was mixed with the following components in the following concentrations: 20 mM HEPES pH  
183 6.5, 9 mM MgCl<sub>2</sub>, 1 mM rNTP mix (NEB), 40 nM of *LwCas13a*, 2 U of Murine RNase  
184 inhibitor (NEB), 25 U of NxGen T7 RNA Polymerase (Biosearch technology), 25 nM of  
185 crRNA and 125 nM of RNaseAlert probe V2 (Invitrogen), in a final volume of 80  $\mu$ L. The  
186 reaction was performed in 384-well plates, F-bottom,  $\mu$ Clear bottom (Greiner) incubated at 37  
187  $^{\circ}$ C in a TECAN plate reader (INFINITE F200 PRO M PLEX), in which 20  $\mu$ L x 3 of each  
188 replicate reaction was distributed. Fluorescence measurements were collected every 10 minutes  
189 up to 3 hours. All SHERLOCK reactions were performed in triplicate and three fluorescence  
190 measurements were taken from each replicate. A negative control template (NCT) was added  
191 in parallel to each independent assay by supplementation nuclease-free water as input.

## 192 **Statistical analysis**

193 The fluorescence intensity values obtained from the TECAN plate reader were analysed using  
194 Excel. For each triplicate reaction at each timepoint, the mean fluorescence intensity value was  
195 divided by the mean of the fluorescence intensity value of the NCT at the same timepoint, to  
196 obtain the fold-change over background fluorescence. The formula used is as follows:

$$\begin{aligned} 197 & \\ 198 & \text{Fold – change over background fluorescence} \\ 199 & = \frac{\text{Mean fluorescence intensity of a triplicate sample reaction at time (x)}}{\text{Mean fluorescence intensity of the triplicate NCT at time (x)}} \end{aligned}$$

200  
201 The graphs and statistical analysis were performed using GraphPad Prism (version 9.3.1)  
202 software. The Shapiro-Wilk normality test was performed to evaluate the type of data  
203 distribution. The non-parametric Mann-Whitney U test or the parametric bilateral unpaired t-  
204 test, with Welch's correction, according to the data distribution results, were used for the  
205 statistical comparison with 95% confidence interval. For multiple comparisons, we applied the  
206 two-stage linear step-up procedure <sup>30</sup>. Multiple sequence alignments were performed using  
207 Clustal Omega <sup>31</sup>.

208

## 209 **Results**

## 210 **Selection of SHERLOCK targets to detect the AQP2/AQP3<sub>(814)</sub> chimera.**

211 We adapted our SHERLOCK4HAT<sup>22</sup> workflow for the detection of markers of resistance to  
212 melarsoprol through the formation of an AQP2/3 chimera (Figure 1A). The AQP2/3<sub>(814)</sub> chimera  
213 independently arose in two distinct HAT foci to currently made up 31.7 % of all known  
214 melarsoprol resistant HAT infections<sup>14,15</sup>. The RPA forward primer amplified from nucleotide  
215 position 705 of the AQP2 sequence, and the RPA reverse primer from position 841, which was  
216 specific to the region AQP3 sequence of the chimera (Figure 1B). The sequences of the wild  
217 type (WT) AQP2 and AQP3 (Tb927.10.14170, Tb927.10.14160, respectively) and that of the  
218 AQP2/3<sub>(814)</sub> chimera (KF564931.1) were aligned to select non-homologous regions between  
219 AQP2 and AQP3 genes for the new primers binding sites (Figure 1B). The crRNA guides were  
220 designed to target the region of the AQP2/3<sub>(814)</sub> chimera that was analogous to AQP2 (Figure  
221 1B). We evaluated three crRNA for the ability to discriminate between RNAs extracted from  
222 *in vitro* derived cells where both AQP2 and AQP3 were knocked out and the AQP2/3<sub>(814)</sub>  
223 chimera was expressed from the rRNA intergenic region<sup>32</sup>, and from wild type *T. b. gambiense*  
224 or *T. b. brucei* cells (Figure 1C). The three crRNAs specifically detected the cells expressing  
225 the AQP2/3<sub>(814)</sub> chimera and did not cross-react with the WT trypanosomes or human cells  
226 (Figure 1C).

## 227 **The AQP2/AQP3<sub>(814)</sub>-specific SHERLOCK assay can be used to identify samples from** 228 **cases of HAT relapses.**

229 After demonstrating that the AQP2/AQP3<sub>(814)</sub>-specific SHERLOCK assay was able to detect  
230 RNA from *in vitro* modified cells, we wanted to investigate whether it could also detect  
231 AQP2/AQP3<sub>(814)</sub>-chimeric RNAs of parasites isolated from patients, from two geographically  
232 distinct locations, showing relapses following treatment with melarsoprol in the Mbuji-Mayi  
233 region of the Democratic Republic of the Congo and Mundri County in South Sudan (Figure  
234 2A), which have been associated with mutations in the AQP2/3 genes<sup>14-16</sup> (Figure 2B). We  
235 tested 4 isolates: (1) a WT strain from a patient infected with *T. b. gambiense* with no mutation  
236 in the AQP2/3 locus and no relapse; (2) the 163AT, 40AT, 349AT and K03048 strains from  
237 patients with HAT relapse infected with *T. b. gambiense* bearing the AQP2/AQP3<sub>(814)</sub>  
238 mutation<sup>14-16</sup>; (3) the MBA strain from a patient with unknown treatment outcome, infected  
239 with *T. b. gambiense* containing an AQP2/3 chimera with the first 677 bp from AQP2, 202 bp  
240 of AQP3 and the last 60 bp from AQP2, termed as AQP2/3<sub>(678-880)</sub>; and the 348BT strain  
241 isolated from a cured patient that contains both AQP2/3<sub>(814)</sub> and AQP2/3<sub>(880)</sub> (first 879 bp



242 from *AQP2*, a point mutation at T869C and the last 60 bp from *AQP3*) chimeras (Figure 2B)  
243 <sup>15</sup>.

244 The sequences of the wild type *AQP2* and 3, the *AQP2/3*<sub>(814)</sub> chimera (KF564931.1),  
245 *AQP2/3*<sub>(880)</sub> (KM282050) and *AQP2/3*<sub>(678-880)</sub> (KM282034) were aligned to select non-  
246 homologous regions between *AQP2* and *AQP3* genes to design a second RPA primer pair  
247 (Figure 2B, Supplementary table 1): the selected RPA forward primer amplified from  
248 nucleotide position 730 of the *AQP2* sequence, and the RPA reverse primer from position 829  
249 of the chimera sequence corresponding to the *AQP3* sequence. Our crRNA guides should not  
250 target the *AQP2/3*<sub>(880)</sub> (KM282050) or *AQP2/3*<sub>(678-880)</sub> (KM282034) chimeras (Figure 2B and  
251 C). We first screened the samples using two pairs of RPA primer and two crRNA guides  
252 (Supplementary figure 1A). The crRNA2 and RPA primer pair 1 were selected to assess the  
253 samples and this SHERLOCK assay was shown to accurately discriminate between patient  
254 samples that contained the *AQP2/3*<sub>(814)</sub> chimera or not (Figure 2D). As expected, the 163AT,  
255 40AT, 349AT and 348 BT samples showed a robust signal in the SHERLOCK *AQP2/3*<sub>(814)</sub>  
256 assay. The K03048 sample from South Sudan scored as positive in the assay, yet it showed a  
257 lower fold-change, likely because the amount of RNA extracted from this sample was low  
258 (Figure 2D). These results confirm that the SHERLOCK *AQP2/3*<sub>(814)</sub> assay can detect the  
259 specific mutation associated with melarsoprol resistance from patient samples.

## 260 **SHERLOCK detection of a single nucleotide variant in the *CPSF3* gene.**

261 Taking advantage of the specificity of SHERLOCK, we developed an assay that can  
262 discriminate between the WT and the *in vitro* derived single nucleotide variant (SNV) of the  
263 *CPSF3* gene (*CPSF3*<sub>(SNV)</sub>, accession number XM\_839191: N<sup>232</sup>H, AAT-CAT), hereon referred  
264 to as *CPSF3*<sub>(SNV)</sub> which confers resistance to acoziborole <sup>19,33</sup>. We first screened RPA primer  
265 pairs that were either 30 nt or 25 nt long (Supplementary figure 1B) and designed to amplify  
266 the region containing the SNV. The RPA primer pair target amplification was assessed using  
267 four different crRNA guides specific for the detection of *CPSF3*<sub>(SNV)</sub>. We observed higher fold-  
268 change values with the 30 nt RPA primer pair as compared to the 25 nt primer pair  
269 (Supplementary Figure 1B). Therefore, we selected the long RPA primer pair for subsequent  
270 optimization of the SHERLOCK assay.

271 Then, 12 crRNA guides were screened for detection of the *CPSF3*<sub>(SNV)</sub>. We designed crRNAs  
272 using the following criteria: 1) setting the SNV complementary base at position 3 (counting  
273 from the 3' end of the crRNA) and the artificial mismatch (if any) at position 5; and 2) setting

274 the SNV complementary base at position 6 and the mismatch (if any) at position 4<sup>23,25,34</sup> (Figure  
275 3A). In addition, we designed crRNAs with spacer lengths shorter than described as optimal for  
276 *LwCas13a* (28 nt,<sup>27</sup>). Indeed, reducing the spacer length to a maximum of 20 nt reduced the  
277 enzyme activity but maintained, or even improved, its ability to discriminate single mismatches  
278 by reducing background fluorescence in the off-target sample<sup>25,34,35</sup> (Figure 3B). Finally, since  
279 consecutive double substitutions in the spacer have been described as effective in the loss of  
280 collateral cleavage activity of the Cas13a enzyme<sup>35</sup>, we also evaluated the efficacy of placing  
281 the synthetic mismatch adjacent to our SNV, in order to generate a double mismatch in the off-  
282 target sequence (Figure 3B).

283 The crRNAs designed to detect the SNV at position 3 showed lower fluorescence emission and  
284 were undetectable when using the crRNAs with a spacer length of 20 or 23 nt (Figure 3B). In  
285 contrast, the crRNAs detecting the SNV at position 6 gave high fluorescence intensity values  
286 with both WT and *CPSF3*<sub>(SNV)</sub>. The fluorescence was reduced only when the length of the spacer  
287 was limited to 20 nt (Figure 3B). The best performing crRNA guide contained the SNV  
288 complementary base at position 6 and a synthetic mismatch at position 4, with a spacer length  
289 of 20 nt (Figure 3B). We then evaluated whether the nucleotide selected as the artificial  
290 mismatch could improve the specificity of the SHERLOCK *CPSF3*<sub>(SNV)</sub> assay. We selected the  
291 best candidate obtained in the first screening (Figure 3B), which used an uracil (U) as the  
292 mismatch (Figure 4A), as well as two other crRNAs, one using cytosine (Figure 4B) and the  
293 other guanine (Figure 4C) as the artificial mismatch. Using either an uracil or a guanine base  
294 as mismatch, the SHERLOCK assays showed statistically significant difference in fluorescence  
295 intensity when comparing total RNAs from *CPSF3*<sub>(SNV)</sub> to WT RNA (Figure 4A and C). Using  
296 a guanine, the fluorescence from the off-target (WT) sequence was reduced to near background  
297 (Figure 4C). These data show that the SHERLOCK assay can be used to detect SNV in *T. brucei*  
298 cells resistant to acoziborole.

## 299 **Discussion**

300 Here we describe the development of new drug resistance SHERLOCK assays for HAT that  
301 could be used for epidemiological surveillance. There are currently no molecular diagnostics  
302 that can screen for emerging drug resistance in HAT patients, yet resistance to all the currently  
303 approved drugs used to treat HAT has been detected either in the field or can be generated in a  
304 laboratory. The two SHERLOCK assays described here can distinguish WT and either gene  
305 chimera's or SNV targets. As an RNA diagnostic, these SHERLOCK assays can be used to

306 screen patients presenting relapse after treatment and could be used to discriminate between  
307 relapse or reinfection, which is critical for adapting drug treatment.

308  
309 Although no longer used for the treatment of gHAT, melarsoprol is still recommended by the  
310 WHO for treatment of rHAT at stage 2 in children or as a second option in adults. Unlike gHAT,  
311 rHAT is an acute infection, with disease progression taking from weeks to months. Resistance  
312 to melarsoprol would, therefore, represent a significant obstacle to control rHAT. In this study,  
313 we have developed a SHERLOCK assay targeting mutations in the *AQP2/3* locus that were  
314 initially identified in circulating parasites by sequencing samples from patients with relapses  
315 after treatment<sup>14,15</sup> . Our high-throughput *AQP2/3*<sub>(814)</sub> SHERLOCK assay detected all parasites  
316 involved in relapses without cross reactivity and could be quickly implemented in reference  
317 labs in the field. One limitation of using SHERLOCK for detecting drug resistance is the  
318 intrinsic dependency of the method on prior knowledge of the gene mutations for the design of  
319 RPA primers and crRNAs. However, by using our existing SHERLOCK4HAT workflow<sup>22</sup>,  
320 the assay could rapidly be adapted and implemented once a mutation has been identified.

321  
322 Acoziborole will likely become the next frontline drug for the treatment of gHAT to move  
323 towards elimination of the disease by 2030<sup>17,36</sup>. Like for the other drugs used to treat HAT,  
324 resistance to acoziborole can be generated in the laboratory through a single point mutation in  
325 the *CPSF3* gene<sup>19,33</sup>. Several SHERLOCK assays have been developed to detect SNV<sup>23,25,34</sup>,  
326 and *LwCas13a*, used in this study, is capable of tolerating mismatches, yet with a reduced  
327 cutting efficient<sup>37</sup>. This could be ameliorated by optimising the crRNA guide length, the  
328 positioning of the mismatch, and/or the Cas13 variant used<sup>34</sup>. In our *CPSF3*<sub>(SNV)</sub> SHERLOCK  
329 assay, we found that the most efficient combination was a 20 nt crRNA, the SNV at position 6  
330 and the synthetic mismatch at position 4. Within the *CPSF3*<sub>(SNV)</sub> SHERLOCK assay, there is  
331 still scope for optimisation to improve the specificity of the assay and which Cas13 variant  
332 could provide better on vs. off target discrimination. In our assays, the nucleotide selected for  
333 the mismatch had the most profound effect on the sensitivity of the assay, especially in the  
334 discrimination between on and off target. Here, the use of a guanine as the mismatch at position  
335 4 showed the best discrimination between the two targets. Should resistance arise from a SNV  
336 or a chimeric gene formation, fully exploiting how the Cas13a-RNA complex is formed will be  
337 key to developing a robust assay for epidemiological surveillance.

338 This study demonstrates the versatility of the SHERLOCK technology to detect known genetic  
339 modifications directly associated to drug resistance, using existing workflows. The major  
340 challenge to develop a SHERLOCK assay is that the targeted genetic mutation must be both  
341 known and stable. However, for rHAT treatment with melarsoprol, we showed that known  
342 resistance mechanisms through the formation of chimeras, that have arisen in geographically  
343 separated regions, are suitable targets for SHERLOCK. Given the adaptability of SHERLOCK,  
344 generating a HAT antimicrobial resistance toolbox will be an invaluable asset for  
345 epidemiological surveillance to screen any cases of relapse. This will be critical not only to  
346 track the incidence of resistance, but also for subsequent selection of the most individually  
347 adapted drug treatment.

348

## 349 **Abbreviations**

350 AQP: Aquaglyceroporin

351 CPSF3: Cleavage and polyadenylation specific factor 3

352 CRISPR: Clustered regularly interspaced short palindromic repeats

353 crRNA: CRISPR RNA

354 HAT: Human African trypanosomiasis

355 HEK: Human embryonic kidney

356 *LwCas13a*: *Leptotrichia wadei* CRISPR-associated protein 13 a

357 NCT: Negative control template

358 NECT: Nifurtimox- eflornithine combination therapy

359 PAM: Protospacer adjacent motif

360 RPA: Recombinase polymerase amplification

361 RT: Reverse transcription

362 SHERLOCK: Specific High-sensitivity Enzymatic Reporter unlocking

363 SNV: Single nucleotide variant

364 SUMO: Small ubiquitin-like modifier

365 WT: Wild-type

### 366 **Acknowledgments**

367 The authors acknowledge the support of the researchers who made this work possible by  
368 providing the necessary genetic materials: *T. b. gambiense* ELIANE cell pellets were provided  
369 by Pr. Annette MacLeod (University of Glasgow, UK); lyophilized RNA extracted from  
370 *CPSF3*-edited *T. b. brucei* were provided by Pr. David Horn (University of Dundee, UK); RNA  
371 from chimeric AQP2/AQP3 *T. b. gambiense* isolates were provided by Dr. Nick Van Reet  
372 (Institute of Tropical Medicine, Antwerp) and Pr. Pascal Maeser (Swiss Tropical and Public  
373 Health Institute, Switzerland).

### 374 **Author contribution**

375 EPA, BR and LG conceived and designed the experiments. EPA and ADH performed the  
376 experiments. EPA, BR and LG analysed the data. BR and LG contributed reagents, materials  
377 and analysis tools. EPA, BR and LG wrote the paper.

### 378 **Funding**

379 This project has received funding from the Agence Nationale pour la Recherche (ANR-PRC  
380 2021 SherPa). The funders had no role in study design, data collection and analysis, decision  
381 to publish, or preparation of the manuscript.

## 382 **Figures and Tables**

383

384 **Figure 1. Detection of the *AQP2/3*<sub>(814)</sub> chimera by SHERLOCK.** (A) Schematic of the *AQP2*  
385 and *AQP3* wild type locus (left) and the *AQP2/AQP3*<sub>(814)</sub> chimera (right). The RPA primers  
386 (arrows) and crRNA target (RNA guide) regions for detection of the *AQP2/AQP3*<sub>(814)</sub> chimera  
387 are shown. (B) Alignments of the chimera *AQP2/AQP3*<sub>(814)</sub> (KF564931.1), WT *AQP2*  
388 (Tb927.10.14170) and *AQP3* (Tb927.10.14160) sequences are shown with the non-  
389 homologous regions highlighted in gray. (C) crRNA screening for the detection of the  
390 *AQP2/AQP3*<sub>(814)</sub> chimera using RNA from in vitro derived *AQP2/AQP3*<sub>(814)</sub>, WT *T.b.b.* (*T. b.*  
391 *brucei*), WT *T.b.g.* (*T. b. gambiense*), and human embryonic kidney (HEK) cells. RNA input at  
392 1 ng/μL. Asterisk represents p values at (\*) p<0.001 and (\*\*) p<0.0001.

393

394 **Figure 2. Evaluation of the *AQP2/AQP3*<sub>(814)</sub> SHERLOCK assay on isolates from HAT**  
395 **patients with relapses associated with the formation of *AQP2/3* chimeras.** (A) Map showing  
396 the regions where patient with relapse after treatment was detected (B) Schematics of the *AQP2*  
397 and *AQP3* loci in 4 different strains isolated from patients in the DRC (WT, 163AT, MBA and  
398 348BT) and South Sudan (K03048). The RPA primers (arrows) and crRNA target (RNA guide)  
399 regions for detection of the *AQP2/AQP3*<sub>(814)</sub> chimera are shown. (C) Alignments of the WT  
400 *AQP2* (Tb927.10.14170) and *AQP3* (Tb927.10.14160); *AQP2/AQP3*<sub>(814)</sub> (KF564931.1);  
401 *AQP2/3*<sub>(880)</sub> (KM282050) and *AQP2/3*<sub>(678-880)</sub> (KM282034) sequences are shown with the non-  
402 homologous regions highlighted in gray. (D) Kinetic representation of the Cas13a reaction  
403 using the *AQP2/3*<sub>(814)</sub>-specific SHERLOCK assay testing the different RNAs extracted from  
404 the 6 strains isolated from DRC patients (163AT, 348BT, 40AT, 349AT, MBA and WT) and  
405 one strain from South Sudan (K03048) (left graph). Representation of the fold-change over  
406 background fluorescence after 180 min (time point taken indicated by black arrow in kinetic  
407 plot) of Cas13a reaction using the *AQP2/3*<sub>(814)</sub>-specific SHERLOCK assay analysing the RNAs  
408 from the different isolated strains (right graph).

409

410 **Figure 3. Optimization of a SHERLOCK assay for the detection of *CPSF3* single**  
411 **nucleotide variant (SNV).** (A) Schematic of the crRNAs design for the detection of the single  
412 nucleotide variant (SNV) in the *CPSF3* gene. Position of the SNV in red and the inclusion of  
413 the synthetic mismatch along the crRNA spacer in green. (B) Screening of crRNAs designed  
414 for the detection of *CPSF3*-edited cells. The target sequence of each crRNA is indicated, as

415 well as the PFS in brackets. crRNAs used for detection of the *CPSF3*<sub>(SNV)</sub>: 1) SNV fixed at  
416 position 3, and 2) SNV fixed at position 6. SNV is in underlined and bold character, and  
417 synthetic mismatch is in underlined, bold and italicized character. crRNAs with different spacer  
418 lengths were evaluated (20, 23 and 27 nt). The heat map shows the fold change over background  
419 fluorescence intensity values collected at time zero and after 3 h of *LwCas13a* detection  
420 reaction. G, guanine; A, adenine; U, uridine; C, cytosine; PFS, protospacer flanking site;  
421 *TbCPSF3*, *Trypanosoma brucei gambiense* cleavage and polyadenylation factor 3; WT, wild  
422 type.

423  
424 **Figure 4. Evaluation of selected nucleotides used as synthetic mismatches in the**  
425 ***CPSF3*<sub>(SNV)</sub> SHERLOCK assay.** Kinetic representation of *LwCas13a* reaction for the selected  
426 base for the synthetic mismatch at nt 4: uracil (A), guanine (B) or cytosine (C). The fold-change  
427 over background fluorescence was indicated at different time points of the *LwCas13a* reaction.  
428 Results from WT cells are shown with open circles and those from edited *CPSF3*<sub>(SNV)</sub> cells with  
429 red dots. Box-plots represent fold-change over background fluorescence intensity values using  
430 RNA from WT cells (gray box-plots) or RNA from *CPSF3*<sub>(SNV)</sub>-edited cells (red box-plots) at  
431 the selected time-point, here indicated by a red arrow in each kinetic plot. RNA input at 5 ng/μL.  
432 The p values are represented by asterisks as follows: p<0.05 (\*), p<0.01 (\*\*), p<0.001 (\*\*\*).  
433

434 **Supplementary Figure 1. RPA primer screening.** (A) Representation of the results obtained  
435 in the screening of RPA primers (1 and 2) and crRNAs (2 and 3) for the AQP2/3<sub>(814)</sub>-specific  
436 SHERLOCK assay using as input the different RNAs from the extraction of strains isolated  
437 from gHAT patients that contains the AQP2/3<sub>(814)</sub> (163AT and 384BT) or not (MBA and WT).  
438 (B) Evaluation of the pairs of RPA longer length primers (30 nt) and shorter length primers (25  
439 nt) by SHERLOCK assay using four potential crRNAs (1 to 4) specific for the detection of  
440 genetic material of *CPSF3*<sub>(SNV)</sub>-edited cells. The data were represented as the fold-change over  
441 background fluorescence, taking the values obtained after 60 min of *LwCas13a* detection  
442 reaction.

443  
444 **Supplementary Table 1. RPA primers and crRNA templates used in this study.**  
445

446 **References**

- 447  
448 1. WHO. Global report on neglected tropical diseases 2024. 2024.  
449 2. WHO. Guidelines  
450 for the treatment of human African trypanosomiasis. *WHO* 2024.  
451 3. Dickie EA, Giordani F, Gould MK, et al. New Drugs for Human African  
452 Trypanosomiasis: A Twenty First Century Success Story. *Trop Med Infect Dis* 2020; **5**(1).  
453 4. Checchi F, Chappuis F, Karunakara U, Priotto G, Chandramohan D. Accuracy of five  
454 algorithms to diagnose gambiense human African trypanosomiasis. *PLoS Negl Trop Dis* 2011;  
455 **5**(7): e1233.  
456 5. Lindner AK, Lejon V, Chappuis F, et al. New WHO guidelines for treatment of  
457 gambiense human African trypanosomiasis including fexinidazole: substantial changes for  
458 clinical practice. *Lancet Infect Dis* 2020; **20**(2): e38-e46.  
459 6. Deeks ED. Fexinidazole: First Global Approval. *Drugs* 2019; **79**(2): 215-20.  
460 7. Pelfrene E, Harvey Allchurch M, Ntamabyaliro N, et al. The European Medicines  
461 Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis. *PLoS Negl*  
462 *Trop Dis* 2019; **13**(6): e0007381.  
463 8. Wyllie S, Foth BJ, Kelner A, Sokolova AY, Berriman M, Fairlamb AH.  
464 Nitroheterocyclic drug resistance mechanisms in *Trypanosoma brucei*. *J Antimicrob*  
465 *Chemother* 2016; **71**(3): 625-34.  
466 9. Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E. Drug resistance in  
467 human African trypanosomiasis. *Future Microbiol* 2011; **6**(9): 1037-47.  
468 10. Baker N, de Koning HP, Maser P, Horn D. Drug resistance in African trypanosomiasis:  
469 the melarsoprol and pentamidine story. *Trends Parasitol* 2013; **29**(3): 110-8.  
470 11. Fairlamb AH, Horn D. Melarsoprol Resistance in African Trypanosomiasis. *Trends*  
471 *Parasitol* 2018; **34**(6): 481-92.  
472 12. Baker N, Glover L, Munday JC, et al. Aquaglyceroporin 2 controls susceptibility to  
473 melarsoprol and pentamidine in African trypanosomes. *Proc Natl Acad Sci U S A* 2012;  
474 **109**(27): 10996-1001.  
475 13. Bassarak B, Uzcategui NL, Schonfeld C, Duszenko M. Functional characterization of  
476 three aquaglyceroporins from *Trypanosoma brucei* in osmoregulation and glycerol transport.  
477 *Cell Physiol Biochem* 2011; **27**(3-4): 411-20.  
478 14. Graf FE, Ludin P, Wenzler T, et al. Aquaporin 2 mutations in *Trypanosoma brucei*  
479 gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol.  
480 *PLoS Negl Trop Dis* 2013; **7**(10): e2475.  
481 15. Pyana Pati P, Van Reet N, Mumba Ngoyi D, Ngay Lukusa I, Karhemere Bin Shamamba  
482 S, Buscher P. Melarsoprol sensitivity profile of *Trypanosoma brucei* gambiense isolates from  
483 cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.  
484 *PLoS Negl Trop Dis* 2014; **8**(10): e3212.  
485 16. Maina NW, Oberle M, Otieno C, et al. Isolation and propagation of *Trypanosoma brucei*  
486 gambiense from sleeping sickness patients in south Sudan. *Trans R Soc Trop Med Hyg* 2007;  
487 **101**(6): 540-6.  
488 17. Betu Kumeso VK, Kalonji WM, Rembry S, et al. Efficacy and safety of acoziborole in  
489 patients with human African trypanosomiasis caused by *Trypanosoma brucei* gambiense: a  
490 multicentre, open-label, single-arm, phase 2/3 trial. *Lancet Infect Dis* 2023; **23**(4): 463-70.  
491 18. Tarral A, Hovsepian L, Duvauchelle T, et al. Determination of the Optimal Single Dose  
492 Treatment for Acoziborole, a Novel Drug for the Treatment of Human African  
493 Trypanosomiasis: First-in-Human Study. *Clin Pharmacokinet* 2023; **62**(3): 481-91.  
494 19. Wall RJ, Rico E, Lukac I, et al. Clinical and veterinary trypanocidal benzoxaboroles  
495 target CPSF3. *Proc Natl Acad Sci U S A* 2018; **115**(38): 9616-21.



- 496 20. Sharma A, Cipriano M, Ferrins L, Hajduk SL, Mensa-Wilmot K. Hypothesis-generating  
497 proteome perturbation to identify NEU-4438 and acoziborole modes of action in the African  
498 Trypanosome. *iScience* 2022; **25**(11): 105302.
- 499 21. Kovarova J, Novotna M, Faria J, et al. CRISPR/Cas9-based precision tagging of  
500 essential genes in bloodstream form African trypanosomes. *Mol Biochem Parasitol* 2022; **249**:  
501 111476.
- 502 22. Sima ND-H, A.; Perlaza, BL.; Ungeheuer, MN.; Rotureau, B.; Glover, L.  
503 SHERLOCK4HAT: a CRISPR-based tool kit for diagnosis of Human African  
504 Trypanosomiasis. *medRxiv* 2022.
- 505 23. Cunningham CH, Hennelly CM, Lin JT, et al. A novel CRISPR-based malaria  
506 diagnostic capable of Plasmodium detection, species differentiation, and drug-resistance  
507 genotyping. *EBioMedicine* 2021; **68**: 103415.
- 508 24. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed  
509 and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. *Science* 2018;  
510 **360**(6387): 439-44.
- 511 25. Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-  
512 Cas13a/C2c2. *Science* 2017; **356**(6336): 438-42.
- 513 26. Myhrvold C, Freije CA, Gootenberg JS, et al. Field-deployable viral diagnostics using  
514 CRISPR-Cas13. *Science* 2018; **360**(6387): 444-8.
- 515 27. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic  
516 acid detection with CRISPR nucleases. *Nat Protoc* 2019; **14**(10): 2986-3012.
- 517 28. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST:  
518 a tool to design target-specific primers for polymerase chain reaction. *BMC Bioinformatics*  
519 2012; **13**: 134.
- 520 29. Piepenburg O, Williams CH, Stemple DL, Armes NA. DNA detection using  
521 recombination proteins. *PLoS Biol* 2006; **4**(7): e204.
- 522 30. Benjamini YaH, Y. Controlling the False Discovery Rate: a Practical and Powerful  
523 Approach to Multiple Testing. *The Journal of the Royal Statistical Society, Series B (Statistical*  
524 *Methodology)* 1995; **57**(1): 289-300.
- 525 31. Sievers F, Higgins DG. Clustal Omega for making accurate alignments of many protein  
526 sequences. *Protein Sci* 2018; **27**(1): 135-45.
- 527 32. Graf FE, Baker N, Munday JC, de Koning HP, Horn D, Maser P. Chimerization at the  
528 AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical  
529 Trypanosoma brucei gambiense isolates. *Int J Parasitol Drugs Drug Resist* 2015; **5**(2): 65-8.
- 530 33. Altmann S, Rico E, Carvalho S, et al. Oligo targeting for profiling drug resistance  
531 mutations in the parasitic trypanosomatids. *Nucleic Acids Res* 2022; **50**(14): e79.
- 532 34. Molina Vargas AM, Sinha S, Osborn R, et al. New design strategies for ultra-specific  
533 CRISPR-Cas13a-based RNA detection with single-nucleotide mismatch sensitivity. *Nucleic*  
534 *Acids Res* 2024; **52**(2): 921-39.
- 535 35. Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al. RNA targeting with CRISPR-  
536 Cas13. *Nature* 2017; **550**(7675): 280-4.
- 537 36. Franco JR, Priotto G, Paone M, et al. The elimination of human African  
538 trypanosomiasis: Monitoring progress towards the 2021-2030 WHO road map targets. *PLoS*  
539 *Negl Trop Dis* 2024; **18**(4): e0012111.
- 540 37. Mantena S, Pillai PP, Petros BA, et al. Model-directed generation of CRISPR-Cas13a  
541 guide RNAs designs artificial sequences that improve nucleic acid detection. *bioRxiv* 2023.
- 542  
543

Figure 1




Figure 2






Figure 3

A



B



**Figure 4**

